Table 1 TKIs for the treatment of advanced HCC

From: URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers

Kinase inhibitors

Targets

References

Sorafenib

RAF1, B-RAF, VEGFR1-3, and PDGFRβ

SHARP4

Lenvatinib

VEGFR1-3, FGFR1-4,PDGFRα, RET, and KIT

REFLECT6

Regorafenib

VEGFR1-3, PDGFRβ, FGFR1-2, RET, KIT, and B-RAF

RESORCE5

Apatinib

VEGFR2

AHELP21

Erlotinib

EGFR

SEARCH22

Donafenib

RAF1, B-RAF, VEGFR1-3, and PDGFRβ

ZGDH37

Back to article page